PSY17 Cost-Utility Analysis of Immune Tolerance Induction (ITI) Therapy Versus On-Demand Treatment With Recombinant FVII (rFVIIa) for Hemophilia A With High Titer Inhibitors in Iran
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.461
https://www.valueinhealthjournal.com/article/S1098-3015(12)02174-2/fulltext
Title :
PSY17 Cost-Utility Analysis of Immune Tolerance Induction (ITI) Therapy Versus On-Demand Treatment With Recombinant FVII (rFVIIa) for Hemophilia A With High Titer Inhibitors in Iran
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02174-2&doi=10.1016/j.jval.2012.08.461
First page :
A680
Section Title :
Systemic Disorders/Conditions
Open access? :
No
Section Order :
1989